Biovail Buys Old Cardizem Name For New Diltiazem Product
Executive Summary
Biovail's purchase of Aventis' Cardizem line will allow the company to market its once-daily diltiazem under an established brand name.
You may also be interested in...
GSK Wellbutrin XL Launch Not Affected By Lost Shipment, Biovail Says
GlaxoSmithKline's ongoing launch of Wellbutrin XL will not be affected by the loss of a product shipment from Biovail's manufacturing facility, Biovail assured analysts during an Oct. 3 teleconference
GSK Wellbutrin XL Launch Not Affected By Lost Shipment, Biovail Says
GlaxoSmithKline's ongoing launch of Wellbutrin XL will not be affected by the loss of a product shipment from Biovail's manufacturing facility, Biovail assured analysts during an Oct. 3 teleconference
Biovail Vasotec/Cardizem Fixed-Dose Combination Data Expected By July
Biovail expects results from a Phase III trial of several fixed-dose combinations of Vasotec and Cardizem XL in the first half of the year